Axel M Gressner
Overview
Explore the profile of Axel M Gressner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
3070
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gressner O, Fang M, Li H, Lu L, Gressner A, Gao C
Clin Chim Acta
. 2013 Mar;
421:126-31.
PMID: 23501329
Still a challenging medical problem is the non-invasive monitoring of patients with a variety of chronic liver diseases being on risk to develop fibrosis, cirrhosis, and, finally, primary liver cell...
2.
Gressner O, Peredniene I, Gressner A
World J Gastroenterol
. 2011 Jan;
17(2):151-63.
PMID: 21245987
Aim: To investigate the mechanisms involved in a possible modulator role of interleukin (IL)-6 signalling on CYR61-CTGF-NOV (CCN) 2/connective tissue growth factor (CTGF) expression in hepatocytes (PC) and to look...
3.
Kuhn J, Gressner O, Gotting C, Gressner A, Kleesiek K
Clin Chim Acta
. 2009 Sep;
409(1-2):123-6.
PMID: 19755118
Background: We investigated the xylosyltransferase (XT) activity in the serum of liver fibrotic patients with hepatitis C virus induced liver fibrosis at different stages as determined according to the scoring...
4.
Gressner O, Beer N, Jodlowski A, Gressner A
Clin Chim Acta
. 2009 Sep;
409(1-2):90-5.
PMID: 19748500
Introduction: Non-invasive, i.e. serum-based assessment of liver fibrosis is still an important diagnostic challenge although multiple single and multiparametric panels of biomarkers have been suggested. Aim: Two approaches were followed...
5.
Weiskirchen R, Meurer S, Gressner O, Herrmann J, Borkham-Kamphorst E, Gressner A
Front Biosci (Landmark Ed)
. 2009 Jun;
14(13):4992-5012.
PMID: 19482601
Fibrosis is a scarring process that is a common feature of chronic organ injury. It is characterized by elevated activity of transforming growth factor-beta resulting in increased and altered deposition...
6.
Gressner O, Gao C, Siluschek M, Kim P, Gressner A
Eur J Gastroenterol Hepatol
. 2009 Mar;
21(9):990-5.
PMID: 19322100
Background And Aim: Next to its role as a carrier protein for vitamin D and its plasma metabolites, the primary function of vitamin D-binding protein (DBP; Gc-globulin) is to serve...
7.
Gressner O, Siluschek M, Lahme B, Gressner A
J Hepatol
. 2009 Mar;
50(5):1053-5.
PMID: 19321219
No abstract available.
8.
Gressner O, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner A
Hepatology
. 2009 Mar;
49(6):2021-30.
PMID: 19309720
Unlabelled: In vivo knockdown of connective tissue growth factor (CTGF/CCN2) was recently shown to attenuate the formation of experimental liver fibrosis. The secreted, cysteine-rich growth factor is proposed to adversely...
9.
Gressner O, Lahme B, Siluschek M, Gressner A
Liver Int
. 2009 Mar;
29(6):886-97.
PMID: 19291178
Background: Recently, we identified hepatocytes as the major cellular source of profibrogenic connective tissue growth factor (CTGF/CCN2) in the liver. Based on reports of a hepatoprotective effect of coffee consumption,...
10.
Antoine M, Kohl R, Tag C, Gressner A, Hellerbrand C, Kiefer P
Biochem Biophys Res Commun
. 2009 Mar;
382(2):359-64.
PMID: 19285038
Cysteine-rich FGF receptor (CFR) was originally identified as a FGF2 receptor and found to be identical to Golgi complex-localized glycoprotein-1 (GLG1), also known as MG-160, and to a murine E-selectin...